David Lewis
Recent Quotes
"This looks to be another strong year for ISRG's revenue and procedure growth."
—
David Lewis, Morgan Stanley
(1/29/13)
more >
"Growth remains above 20% in Diagnostics for HAE."
—
David Lewis, Morgan Stanley MS:NYSE
(10/30/12)
more >
"Quarterly volatility in ISRG results could provide a more attractive entry point."
—
David Lewis, Morgan Stanley MS:NYSE
(9/28/12)
more >
"Receipt of the CE Mark validates benefits of HAE's Solx technology."
—
David Lewis, Morgan Stanley
(9/18/12)
more >
"HAE has multiple levers it can pull to drive earnings growth."
—
David Lewis, Morgan Stanley MS:NYSE
(8/3/12)
more >
"The Pall deal may help commercialize HAE's whole blood solution."
—
David Lewis, Morgan Stanley
(4/30/12)
more >
"HAE's top-line guidance was consistent with our ~6% growth in FY13."
—
David Lewis, Morgan Stanley
(1/31/12)
more >
